Cargando…
Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
Comprehensive characterization of the genomic landscape of epidermal growth factor receptor (EGFR)-mutated lung cancers have identified patterns of secondary mutations beyond the primary oncogenic EGFR mutation. These include concurrent pathogenic alterations affecting p53 (60–65%), RTKs (5–10%), PI...
Autores principales: | Gini, Beatrice, Thomas, Nicholas, Blakely, Collin M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330397/ https://www.ncbi.nlm.nih.gov/pubmed/32642201 http://dx.doi.org/10.21037/jtd.2020.03.78 |
Ejemplares similares
-
Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
por: Velazquez, Ana I., et al.
Publicado: (2020) -
EGFR targeted therapy resistance: current status, challenges, and future outlook
por: Bivona, Trever G.
Publicado: (2020) -
Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Justin A., et al.
Publicado: (2020) -
Applications of cell-free circulating tumor DNA detection in EGFR mutant lung cancer
por: Bulbul, Ajaz, et al.
Publicado: (2020) -
Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)